<DOC>
	<DOCNO>NCT02954029</DOCNO>
	<brief_summary>Arterial access key step endovascular treatment cardiovascular disease . This study design confirm safety efficacy hemostasis pad use chitosan patient undergo percutaneous procedure arterial approach . Two cohort include study : transradial transfemoral cohort . Among transfemoral cohort , safety efficacy ezClot pad compare BloodSTOP® pad ( LifeScience PLUS , Palo Alto , CA , USA ) . The BloodSTOP® pad etherize oxidize regenerate cellulose matrix achieves hemostasis activate intrinsic coagulation pathway . The hypothesis test among transradial cohort combine use hemostasis pad compression device superior compression device term hemostasis patient underwent tranradial coronary procedure .</brief_summary>
	<brief_title>Hemostasis Pad Using Chitosan After Invasive Percutaneous Procedures</brief_title>
	<detailed_description>Arterial access key step endovascular treatment cardiovascular disease . However , failure hemostasis arterial access site associate high risk complication bleed , pseudoaneurysm , arteriovenous fistula . Major bleed event percutaneous coronary intervention show associated poor short-term well long-term prognosis . Thus , variety approach quickly effectively achieve hemostasis puncture site . The traditional method apply manual compression follow simple dress directly puncture site . Despite long history economic advantage , method require prolonged hemostasis time , substantial effort train practitioner , patient ' discomfort . Use hemostasis pad accelerate blood clot become effective alternative . The ezClot pad new product use chitosan , deacetylated complex carbohydrate derive naturally occur substance chitin . The positively charge chitosan molecule attract negatively charge blood cell platelet , thus promote clot . The ability hemostasis chitosan proven HemCon® pad ( HemCon Medical Technologies , Inc. , Portland , OR , USA ) . This study design confirm safety efficacy ezClot pad patient undergo percutaneous procedure arterial approach . Two cohort include study : transradial transfemoral cohort . Among transfemoral cohort , safety efficacy ezClot pad compare BloodSTOP® pad ( LifeScience PLUS , Palo Alto , CA , USA ) . The BloodSTOP® pad etherize oxidize regenerate cellulose matrix achieves hemostasis activate intrinsic coagulation pathway . Transradial approach increase use coronary procedure . The important benefit transradial approach compare transfemoral approach low risk major bleeding . Widely use method hemostasis radial puncture sit manual device-assisted compression . There yet limit data regarding use hemostasis pad transradial approach . The hypothesis test transradial cohort combine use hemostasis pad compression device superior compression device term hemostasis patient underwent transradial coronary procedure .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Hemostatics</mesh_term>
	<mesh_term>Chitosan</mesh_term>
	<criteria>age 18 year old patient undergo invasive procedure via radial femoral artery congenital acquire bleeding tendency platelet count &lt; 50,000/ μL hypersensitivity shrimp , lobster beetle</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>